June30 , 2026

    China grants zero duty to Indian pharma as US blocks imports with 100% tariff

    Related

    India-Bound Shipping Through Strait of Hormuz Rises Despite Renewed West Asia Tensions

    Despite renewed geopolitical tensions in West Asia, India-bound maritime...

    Andhra Pradesh Rationalises Coastal Jurisdiction of Ramayapatnam, Machilipatnam Ports

    The Andhra Pradesh Government has rationalised the notified geographical...

    Syama Prasad Mookerjee Port Targets 74 MT Cargo Handling in FY 2026–27

    Syama Prasad Mookerjee Port has set an ambitious target...

    VOC Port Registers 42.61% Growth in Oil Cake/Copra Cargo Handling

    V.O. Chidambaranar Port Authority has recorded a robust 42.61%...

    Share

    In a major development, China has slashed the 30 percent import duty on Indian pharmaceutical products to zero. This landmark step will allow Indian drug manufacturers to export medicines to China without paying any customs duty. Experts say this decision could boost Indian pharma exports by billions of dollars in the coming years.

    Timing important as US raises tariffs

    The announcement comes just after US President Donald Trump imposed a 100 percent tariff on pharma imports, a move that could hurt India’s large drug-exporting industry. With the US market becoming costlier, China’s decision offers Indian companies an alternative market with strong demand for affordable medicines.

    Why it matters for India

    India is known as the ‘pharmacy of the world,’ supplying affordable generic drugs and vaccines across the globe. The Chinese market, with its huge population and growing healthcare needs, has long been difficult for Indian exporters due to high duties. Now, with a zero percent duty, Indian companies will have a level playing field and better access to one of the world’s largest healthcare markets.

    Experts see big opportunity

    Trade analysts believe this move will help balance India-China trade relations, which are often tilted in Beijing’s favour. Pharma industry leaders also expect this change to create thousands of jobs in India, boost revenues, and strengthen India’s position in global healthcare supply chains.

    spot_img